PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3986.96%
Revenue growth of 3986.96% while CRVO is flat. Bruce Berkowitz would check if a small edge can widen further.
804.39%
Gross profit growth above 1.5x CRVO's 100.00%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
35.83%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
35.83%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
36.40%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
37.84%
Positive EPS growth while CRVO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
37.84%
Positive diluted EPS growth while CRVO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
2.81%
Share count expansion well above CRVO's 0.00%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.81%
Diluted share count expanding well above CRVO's 0.00%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-14.43%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-14.57%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1885.22%
Negative 10Y OCF/share CAGR while CRVO stands at 99.99%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
90.95%
5Y OCF/share CAGR is similar to CRVO's 99.06%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
81.42%
3Y OCF/share CAGR at 75-90% of CRVO's 94.10%. Bill Ackman would press for improvements in margin or overhead to catch up.
-991.23%
Negative 10Y net income/share CAGR while CRVO is at 99.91%. Joel Greenblatt sees a major red flag in long-term profit erosion.
94.68%
5Y net income/share CAGR similar to CRVO's 99.89%. Walter Schloss might see both on parallel mid-term trajectories.
84.15%
3Y net income/share CAGR 75-90% of CRVO's 94.54%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
1611.09%
10Y equity/share CAGR above 1.5x CRVO's 100.08%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-55.02%
Negative 5Y equity/share growth while CRVO is at 101.08%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
127.30%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.96%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-36.45%
We’re deleveraging while CRVO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-19.33%
Our R&D shrinks while CRVO invests at 61.24%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-34.65%
We cut SG&A while CRVO invests at 10.01%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.